B iological markers that objectively indicate someone's medical status have been identified for many diseases; for example, in oncology, these biomarkers revolutionized cancer diagnosis and treatment. 1 In addition, in psychiatry, such prospects inspired a quest for the identification of biomarkers for health and disorder, 2-4 using, for example, candidate gene approaches. 5 However, the complex etiologic and biological mechanisms of mental disorders and a fundamental reliance on symptom-based diagnoses have hindered progress. Psychiatry is now the last area of medicine in which diseases are diagnosed solely on the basis of symptoms, and biomarkers to assist treatment remain to be developed. To bring precision medicine to psychiatry, largescale international initiatives work toward stratifying mental disorders into biologically more homogeneous subtypes based on the integration of many levels of information across multiple dimensions of functioning. 4, 6 The most significant obstacle toward finding accurate and reliable biomarkers in mental disorders is their extreme heterogeneity 7 based on current psychiatric nosology. Heterogeneity can be observed on at least 3 levels: (1) heterogeneity as a consequence of different symptom profiles that are classified under the same disorder (clinical heterogeneity), (2) heterogeneity induced by different biological predispositions converging on the same symptoms (biological heterogeneity), and (3) different environmental events that cause (or prevent) the same symptoms (environmental heterogeneity). Case-control designs, which assume that patient and control groups are distinct entities, are overwhelmingly dominant in psychiatry but are limited to detecting group differences that essentially describe an average patient. They neglect interindividual differences, which are crucial for mapping the heterogeneous disease phenotype at the level of the individual. 8 Schizophrenia and bipolar disorder are excellent examples of highly heterogeneous mental disorders. 9, 10 They have been linked to multiple brain systems and neural processes, which become perturbed throughout development through complex interactions between the individual's genetic architecture and environmental stressors. 9, 11 Both disorders have been linked to transdiagnostic impairments in the dopamine system. 12 However, because these conclusions are based on group-level comparisons, they provide limited information about disease mechanisms in individual patients. This study aimed to quantify the brain structural heterogeneity in adults with schizophrenia and bipolar disorder by mapping regional brain alterations at the level of individual participants. We hypothesized that group-level differences only represent a small part of the neurobiological abnormalities that characterize these disorders and that highly individual deviations from the norm comprise the bulk of these abnormalities. To test this hypothesis, we used a normative modeling approach that maps interindividual differences in reference to the healthy range. A normative model can be understood as a statistical model that maps demographic or behavioral variables to a quantitative brain readout. 13 Similar to growth charts used in somatic medicine, in which a child's height is compared with the normative distribution for height at a particular age, a normative model can be used to characterize individuals in reference to a normative brain structure at a particular age. 13, 14 Using this approach, we provide a route toward precision medicine in psychiatry in that we provide quantitative estimates of the heterogeneity among patients with schizophrenia and bipolar disorder by investigating the degree of spatial overlap in deviations from the normative model and chart the heterogeneity in alterations of brain structure across these disorders and at the level of the individual patient.
Methods

Participants
All participants were recruited as part of the Thematically Organized Psychosis study from October 27, 2004, to October 17, 2012 . Data were reanalyzed in 2017 and 2018. Patients were recruited from inpatient and outpatient clinics in the Oslo area of Norway. Patients (aged 18-65 years) understood and spoke a Scandinavian language, had no history of severe head trauma, and had an IQ above 70. Patients were assessed by trained physicians or clinical psychologists. 15 Psychiatric diagnosis was established using the Structured Clinical
Interview for DSM-IV Axis I Disorders. 16 Healthy individuals were randomly sampled from national registries if neither they nor their relatives had a psychiatric or alcohol or substance use disorder or any cannabis use during the past 3 months. All participants completed a neuropsychological test battery, including verbal learning and memory, processing speed, working memory, and executive functioning. Written informed consent was obtained from all participants. Magnetic resonance imaging as well as cognitive and clinical data were deidentified. The study was approved by the Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate. More details and a description of magnetic resonance imaging acquisition and processing are given in the eMethods in the Supplement.
Normative Modeling
We estimated a normative brain aging model by using gaussian process regression to predict regional gray and white matter volumes across the brain from age and sex using voxelbased morphometry-derived gray and white matter maps.
Key Points
Question Is the focus on the average patient disguising interindividual differences among patients with mental disorders?
Findings In this study of magnetic resonance imaging data from 218 patients with schizophrenia spectrum disorders and 256 healthy control individuals, mapping of interindividual differences in brain structure revealed that only a few brain loci had the same abnormalities in more than 2% of patients with the same disorder despite robust group-level differences in multiple brain regions between patients and control individuals.
Meaning These findings suggest that the idea of the average patient is a noninformative construct that falls apart when mapping interindividual differences and provide a framework toward precision medicine in psychiatry.
To supplement this analysis and to characterize volumetric differences more precisely, we also estimated normative models using Freesurfer-derived cortical thickness and pial area measures (eMethods in the Supplement). To avoid overfitting in the normative models, it is crucial to estimate performance out of sample. Therefore, we estimated the normative range for this model in healthy individuals under 10-fold cross-validation, then applied the model trained on all data to patients. Normative models were estimated using gaussian process regression, 17 yielding coherent measures of predictive confidence in addition to point estimates. Such measurement was important because we used this uncertainty measure to quantify the deviation of each patient from the group mean at each brain locus. Thus, we were able to statistically quantify deviations from the normative model with regional specificity by computing a z score for each voxel that reflected the difference between the predicted volume and the true volume normalized by the uncertainty of the prediction. 13 We estimated mean deviations from the normative model in healthy individuals, patients with bipolar disorder, and patients with schizophrenia using Permutation Analysis of Linear Models (PALM) on the normative deviation maps, 18 which allows for permutation-based inference using t tests. PALM was used to create a map of z values for each of these groups. We established the threshold for those maps using z = ±2.6 (ie, P < .005) to make them comparable with individual maps of deviation, explained below. Furthermore, we determined multiple comparison-corrected, threshold-free, cluster-enhanced and modality-corrected differences between the groups. The threshold for individual deviation maps was established at |z|>2.6 (ie, P < .005), and extreme positive and extreme negative deviations from the normative model were defined based on this threshold. We chose to use a single fixed threshold for statistical significance for each participant individually because it simplifies the comparison across individuals relative to the alternative approach of controlling the false discovery rate (FDR) separately for each participant. 13 Specifically, although FDR controls for multiple comparisons, this process is at the expense of estimating a separate threshold for each participant. Therefore, it is insensitive to an overall shift in deviations from the normative model for 1 individual. In other words, an individual with small reductions in gray matter across the entire cortex may seem to have normal findings using an FDR thresholding procedure because the overall distribution of deviation is shifted for this individual. However, we also performed the analyses again controlling the FDR at the individual participant level using the Benjamini and Hochberg procedure. 19 These analyses are reported in the eMethods in the Supplement and led to identical conclusions. All extreme deviations were combined into scores that represented the percentage of extreme positive and negative deviating voxels for each participant, expressed relative to the total number of intracerebral voxels. We tested for associations between diagnosis and those scores using a χ 2 test, corrected for multiple comparisons using the BonferroniHolm method. 20 To assess the extent of those extreme deviations spatially, we created individualized maps and calculated the voxelwise overlap among individuals from the same groups. The overlap for the clinically less homogenous group of patients with schizophrenia spectrum disorder are given in the eResults in the Supplement. Finally, we tested for associations between the percentage of extremely deviating voxels and age, disease duration, and cognitive performance. We corrected for the number of regressions (n = 12) within each disorder and modality using the Bonferroni-Holm method.
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A corrected threshold P < .05 was considered to be statistically significant. All analyses were performed with Python software, version 3.6 (Python Software Foundation). We performed additional checks to eliminate the possibility of nuisance effects of scanner artifacts (eg, head motion), medication, and substance abuse confounding our results (eResults in the Supplement).
Results
A total of 218 participants with schizophrenia spectrum disorders were included (mean 
Normative Model
In Figure 1 , we depict a spatial representation of the voxelwise normative model, which was characterized by a global gray matter decrease from 20 to 70 years of age, particularly in the frontal and cerebellar regions, with the largest decrease primarily in the frontal areas for both women and men. In contrast, the normative model of white matter was characterized by decreases and increases across the adult lifetime for both women and men. Figure 2 shows mean group differences with respect to the normative model among healthy individuals (under crossvalidation), patients with schizophrenia, and those with bipolar disorder in gray and white matter, corrected for modalities and multiple comparisons. In gray matter, patients with schizophrenia had greater mean negative deviations than did healthy individuals in frontal, temporal, and cerebellar regions; mean deviations were also more negative in patients with schizophrenia than in patients with bipolar disorder and were localized primarily in fontal brain regions. In white matter, we observed differences comparable to those described for gray matter.
Mean Deviations Compared Across Patients and Healthy Individuals
Extreme Deviations Compared Across Patients and Healthy Individuals
In gray matter, patients with schizophrenia had a higher percentage of extreme negative deviations across voxels (0.9% of voxels) compared with healthy individuals (0.23% of voxels, indicated that healthy individuals differed from patients with schizophrenia and bipolar disorder (Wald χ 2 = 14.99, P = .001, corrected P = .004); this finding was associated with a larger percentage of extreme positive deviations in healthy individuals (1.08% of voxels) than in patients with bipolar disorder (0.79% of voxels, P = .001) and schizophrenia (0.78% of voxels,
In white matter, patients with schizophrenia differed from healthy individuals and patients with bipolar disorder in terms of the percentage of extreme negative deviations (Wald χ 2 = 64.14, P < .001, corrected P<.004), with a larger proportion of extreme negative deviations in patients with schizophrenia (0.62% of voxels) than in healthy individuals (0.25% of voxels, P < .001) and in patients with bipolar disorder (0.41% of voxels, P = .001). In the percentage of extreme positive deviations across groups, healthy individuals differed from patients with schizophrenia and bipolar disorder (Wald χ 2 = 13.48, P = .001, corrected P<.004); a higher proportion of extreme positive deviations was seen in healthy individuals (1.14% of voxels) than in those with schizophrenia (0.83% of voxels, P = .003) and bipolar disorder (0.83% of voxels, P = .001) ( Figure 2D -F). Figure 3 shows that, on average, healthy individuals did not typically deviate substantially from the normative model. Although we observed a scattered pattern of positive deviations on the overlap maps, no negative deviation was found in the mean or in the overlap maps. Figure 4 shows that patients with schizophrenia had mean negative deviations from the normative model in frontal, superior parietal, and the cerebellum gray matter as well as positive deviations in the basal ganglia. The overlap maps for individuals with schizophrenia were dominated by extreme negative deviations in these regions. At least 2% of patients had extreme deviations in those regions. In addition, in white matter, patients with schizophrenia had widespread extreme negative deviations from the normative model, with focal hotspots in frontal, temporal, and cerebellar regions. The pattern for all patients belonging to the schizophrenia spectrum (also including patients with schizoaffective and schizophreniform disorder) was the same as for the restricted set with schizophrenia (eFigure 1 in the Supplement). Figure 5 shows that in patients with bipolar disorder, there were mean deviations in cerebellar, temporal, and thalamic regions. Mean effects for the deviations were not substantially affected by outliers (eFigure 6 in the Supplement). The deviations were predominantly negative, indicating that, typically, these patients had lower gray matter volume in those regions than estimated to be normative by the model. The overlap maps corresponded only marginally with this pattern; however, in the thalamic region, more than 2% of the patients had extreme negative values. We observed positive deviations in the caudate, which was supported by the overlap maps. In white matter, we observed negative deviations, in particular in the brainstem, temporal, and frontal regions. The distribution across individuals is shown using histograms of the percentage of deviating voxels in eFigure 2 in the Supplement and examples of individuals with extensive deviations in eFigure 3 and eFigure 4 in the Supplement.
Spatial Extent of Extreme Deviations Across Patients and Healthy Individuals
Overlap maps using FDR (eFigure 5 in the Supplement)were slightly sparser but consistent with our main results. Individual extreme deviations within the different patient groups were linked to cognitive performance and disorder duration but not to age (eTable 2 in the Supplement). Furthermore, performing the analyses again using Freesurfer-derived cortical thickness and pial area measures produced nearly identical results and showed that extreme deviations were principally attributable to a thinning of the cortex in patients with schizophrenia and bipolar disorder (eFigures7and8intheSupplement).
Discussion
We mapped the biological heterogeneity of schizophrenia and bipolar disorder in reference to normative brain aging across the adult lifespan. We found that in patients with schizophrenia, the frontal regions, the cerebellum, and the temporal cortex usually (ie, in the average patient) had reduced cortical volume compared with a healthy lifespan trajectory. For the average patient with bipolar disorder, this pattern was less pronounced and primarily present in cerebellar regions. This finding is in line with earlier, well-powered group comparison studies 21-25 that reported small to medium effects. Of more importance, we found that these mean deviations masked extreme interindividual differences. Only a few brain loci had extreme deviations in more than 2% of the patients. In this study, patients with schizophrenia and bipolar disorder differed extremely on an individual level; the lack of substantial overlap among patients in terms of extreme deviations from the normative model is evidence of the high degree of biologi- 
White matter volume
The mean differences were corrected for modalities and multiple comparisons. A-C, In gray matter, healthy individuals had stronger mean negative deviations than individuals with schizophrenia, especially in the frontal, temporal, and cerebellar regions; furthermore, individuals with bipolar disorder had stronger mean negative deviations than healthy individuals in the cerebellum. Patients with bipolar disorder had weaker mean negative deviations than patients with schizophrenia in the frontal and temporal brain regions but not in the cerebellum. D-F, In white matter, the differences were comparable to those observed in gray matter. Healthy individuals had no regions with significant deviations in either gray or white matter. Scale indicates corrected P values.
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Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models cal heterogeneity of both disorders. This finding is in line with the notion that mental disorders are complex, with little sharing of causal brain structural defect, genetic variants, or environmental stressors. Schizophrenia was conceptualized as a polygenic disorder half a century ago, 26 consistent with published identification of genetic risk factors. 27 Together with our current results on neuroimaging-based evidence of heterogeneity, these findings corroborate that the categorization of mental health disorders, as defined using current diagnostic manuals, does not conform with biology 3, 4, 28 ; such work also emphasizes the need to develop tools for clinical stratification and characterization spanning conventional diagnostic boundaries, such as in the Research Domain Criteria. 4 A previous study 29 that used a classic case-control design did not identify biological signatures for schizophrenia or bipolar disorder informative enough for individualized estimations. In practice, the discriminative capability of candidate biological signatures is most commonly studied using multivariate pattern classifiers that integrate a large number of features in a single model. However, in patients with schizophrenia and bipolar disorder, these discriminative patterns do not identify the diagnostic categories with an accuracy that can be considered to be clinically useful, especially in large samples. [29] [30] [31] The present results suggest that this outcome is possibly a result of collapsing individual patients with different biological signatures into a single diagnostic group. Furthermore, even though the biological stratification of mental disorders may be useful, 3, 4, 6, 32 our results suggest that potentially emerging biological strata are likely smaller than previously anticipated. Interindividual differences are vast, and we estimate that those differences will not easily boil down to reliable and robust biological subtypes of mental disorders. Published studies 33-35 that compared the estimated age with the true age of a patient have suggested that schizophrenia is characterized by accelerated brain aging in contrast to bipolar disorder. The present results are in line with those general findings; however, we also found deviations from the normative pattern in patients with bipolar disorder. Of more importance, we found that high interindividual differences were a hallmark for both disorders in gray and white matter; however, the mapping of differences at the level of the individual patient is not possible using the brain age approach because it relies exclusively on group comparisons. A point of consideration in this context is that the individual deviations that we observed may be functionally related (eg, concentrated in functionally related brain areas). If so, our results suggest that brain networks are unlikely to be affected in The top panel shows a map of group-level mean deviations (|z| > 2.6). The bottom 2 panels show the percentage of extreme deviations from the normative model at each brain locus, that is, an extreme value of |z| > 2.6. On average, frontal regions, the cerebellum, and the temporal cortex had negative deviations in schizophrenia. Deviations overlapped little, with only a few brain loci showing extreme deviations in more than 2% of the patients.
Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models the same way across patients, but different structural abnormalities may impair the working of a specific functional network via different mechanisms, 36,37 converging on similar symptoms.
Although testing this hypothesis was beyond the scope of this study, we are planning work to combine functional and structural measures to better chart the nature of abnormalities in schizophrenia and bipolar disorder and aim to map the multimodal heterogeneity of both disorders. [38] [39] [40] The present work is the start of a research line that aims to systematically map the heterogeneity of mental disorders across biological readouts in the spirit of precision medicine. A logical next step is to apply clustering algorithms to the deviations from normative models to find subtypes, similar to other subtyping approaches. 41, 42 However, this step is best performed in larger samples and requires extensive validation to ensure that clusters are present in the data and are clinically relevant, although normative modeling can also be used even if there are no clearly defined subtypes in the data.
13,14
Limitations A limitation of this study is that it does not permit strong inferences about the degree to which certain confounding variables may have influenced our findings. We did not find evidence of confounding effects of medication but found minor associations between overall image quality and substance abuse with nega- tive deviations in gray matter for schizophrenia (eTables 3-5 in the Supplement). However, the measures that we used to assess this effect are crude, and our design does not permit inferences about the direction of causality (eg, patients with greater severity may move more in the scanner and be more prone to drug abuse). These issues should be more fully addressed in future studies.
Conclusions
Our results have important implications for case-control designs in (neuroimaging-based) psychiatric research because we found little overlap among individual patients with the same disorder. This finding agrees with the notion that severe mental disorders are complex, with highly polygenic and multifactorial causes; the findings also provide a step toward a systematic mapping of the heterogeneity of these disorders. Although the shift from group-level psychiatry toward precision medicine has only just started, on the basis of these results, it appears that appropriate ways to incorporate interindividual differences may determine the success of the transition. Our results suggest that a full understanding of the biological features underlying schizophrenia and bipolar disorder may not be achieved by studying the average patient but by mapping patients' individual pathophysiologic signatures. 
eMaterials
These online materials contain information on eMethods, eResults, eTables, and eFigures referred to in the main text of the manuscript.
eMethods
MRI acquisition
Structural scans were obtained on a 1.5 Tesla Siemens MAGNETOM Sonata scanner (Siemens Medical Solutions, Erlangen, Germany) using a standard head coil. 
Estimation of gray and white matter volume
We chose voxel-based morphometry (VBM) as the primary processing framework for the T1-weigted images over alternatives such as Freesurfer due to the benefit of the VBM pipeline that it treats subcortical, cerebellar and cortical structures consistently. This is important for our work as earlier research has shown that those structures are important in schizophrenia and bipolar disorder [1] [2] [3] [4] and we wanted to rule out methodological bias between these regions in our normative modeling approach. However, to increase confidence in our findings and to better characterize volumetric differences in the cortex we additionally report the latter analyses in the supplement. In future work, we will also add alternative measures and data from different modalities to map the heterogeneity, which may provide more specific inferences about the biology underlying abnormalities in these disorders in the cortex.
Raw structural MRI images were preprocessed using the computational analysis version 12 (CAT12; http://www.neuro.uni-jena.de/software/) 5 . This toolbox is based on statistical parametric mapping version 12 (SPM-12). Images were segmented, normalized, and bias-field-corrected using VBM-SPM12 (http://www.fil.ion.ucl.ac.uk/spm, London, UK) 6, 7 , yielding images containing gray and white matter segments. Prior to the estimation of the normative models, all gray and white matter volumes were smoothed with an 8 mm FWHM Gaussian smoothing kernel.
Estimation of cortical thickness and surface area
Structural MRI images were preprocessed using Freesurfer v5.3 software to extract measures for cortical thickness and areal expansion (http://surfer.nmr.mgh.harvard.edu/; 8, 9 ). The standard FreeSurfer preprocessing pipeline (recon-all) was applied to these images, in which a reconstruction of the cortical sheet was estimated using intensity and continuity information. Cortical thickness was determined as the closest distance from the gray/white boundary to the gray/cerebrospinal fluid (CSF) boundary at each vertex 10 . Surface area in Freesurfer is estimated as relative amount of expansion or compression at each vertex when registering each participant's surface to a common atlas. Surface maps were resampled and mapped to a common coordinate system 11 . During preprocessing, the data were registered onto the high-resolution average participant surface space (fsaverage), and a 10 mm FWHM surface-based smoothing kernel was applied.
Cognitive measures
Verbal learning and memory, was derived from the logical memory subtest of the Wechsler memory scale 12 and the California verbal learning test 13 , processing speed from the digit symbol test from the Wechsler adult intelligence scale (WAIS-III) 14 , working memory from the digit span test of the WAIS-III 14 , and executive function from the verbal fluency test (Delis-Kaplan Executive Function System (D-KEFS) 15 and the color word interference test (D-KEFS) 15 . These same measures were used in an earlier study 16 .
Prior to association of the cognitive measures with the percentage of extreme negative and extreme positive deviations, missing values were imputed by the mean. The imputation rate for verbal learning and memory was 6.2%, for processing speed 6.6%, for working memory 6.2%, and for executive functioning 6.6%.
Potential confounding variables
We performed additional checks on our models to eliminate the possibility of image quality (e.g. due to head motion), medication and substance abuse confounding our results. Regarding image quality, we carefully checked the quality of all MRI scans included in our model using the 'weighted overall image quality' metric provided by the CAT12 toolbox. Whilst this does not assess the effect of head motion directly, it provides a reasonable estimate of overall image quality which is influenced by head motion. On this metric, all participants included in our cohort scored < 2.8, where lower scores denote higher image quality. On the rating scale provided by the authors of this tool (see www.neuro.uni-jena.de/cat/index.html#QA), this corresponds to a rating of 'good' for 99.1%
of our scans and a small number (0.9%) as 'satisfactory'.
To check whether medication effects could have confounded our results, we regressed the percentage of extreme positive and negative deviations with the normalized total medication load separately for the group of individuals with schizophrenia and bipolar disorder. This was computed by dividing the raw dosage of each medication by the directed daily dosage for that medication (see https://www.whocc.no/atc_ddd_index/), then summing across all medications for each individual. We emphasize strongly that these associations should be considered illustrative only because our study was not designed to detect medication effects and has multiple limitations for that purpose: it follows a cross-sectional design with no random assignment to medication type and dosage and almost all patients (and no controls) have been medicated. We also did not acquire plasma concentrations of drugs or metabolites, nor accurate life-time measures of medication. We then correlated image quality measures and medication load with the percentage of positive and negative deviations for each subject (see main text). Further we checked if substance abuse could have influenced our analyses. We tested this by comparing the difference between individuals that abused drugs and those that do not on the percentage of extreme positive and extreme negative deviations, separately for patients with schizophrenia and bipolar disorder. For this we combined a measure of lifetime drug abuse from the SCID 17 with a measure from a custom survey (assessing ongoing drug abuse). Since this results in a large number of comparisons, we correct these using the same Bonferroni-Holm method we use for the main analyses (separately for each potential confounding variable).
Normative modelling on cortical thickness and surface area
We repeated an identical normative modelling procedure but instead of VBM whiteand gray matter maps we utilized measures of cortical thickness and surface area. We used age and gender as a predictor for these brain features, using the normative modelling approach described in the main text.
eResults
Deviations across the full schizophrenia spectrum
In eFigure 1, we show the group level deviations including all individuals in the schizophrenia spectrum (i.e. including schizoaffective and schizophreniform disorder).
See main text for details.
Distribution of deviations across all subjects
In eFigure 2, we show histograms characterizing the distribution of the total percentage of deviating voxels across participants. For all disorders this distribution is sharply peaked, slightly asymmetric and with heavy tails. Taken together with Figure 
False discovery rate corrected deviations
In eFigure 5, we show the group-level deviations after correcting for the false discovery rate (FDR). These are highly similar to the maps of deviation from the models including only pure schizophrenia ( Figure 4 in the main text).
Characteristics of the sample
In eTable 1, we report the demographic and clinical characteristics of participants in this study.
Individual extreme deviations linked to cognitive performance and disorder duration, but not age
In eTable 2, all significant associations that survived multiple comparisons are displayed. In schizophrenia, the number of extreme positive white matter deviations associated positively with disease duration. The number of extreme deviations were not significantly associated with age in any of the groups. In bipolar disorder, the number of extreme negative deviations associated significantly with processing speed and executive functioning; the more negative deviations a patient exhibited in gray matter, the lower their processing speed and executive functioning.
Potential confounding variables
The results from the analyses of potential confounding variables is reported in eTable 3 (image quality), eTable 4 (medication) and eTable 5 (substance abuse).
Regarding image quality, the only significant association we detected was a moderate positive correlation with the percentage of extreme negative deviations in gray matter with overall image quality (i.e. more substantial negative deviations were associated with lower image quality). The image quality metric is quite general and is sensitive to many factors (e.g. head motion or pathology). Indeed, patients often move more in the scanner than controls. To better understand the nature of this variation, we performed two additional regression analyses to test if the explained variance between image quality measures and the reported diagnostic effect on the percentage of extreme negative deviations was shared. We could show that these effects are not shared, as the effect without correction © 2018 American Medical Association. All rights reserved.
for image quality measures of the diagnosis ( = 0.203; p < 0.001) was virtually the same as with correction ( = 0.196; p < 0.001). This gives us confidence that this has no significant impact on the main conclusions of this manuscript. Nevertheless, this does highlight that for future studies, it is desirable to acquire different measures and develop methods that allow these potential effects to be better identified. Regarding medication,
we report a nominally significant association between positive deviations in white matter and total medication load, but this did not survive correction. Regarding substance abuse we find a significant association with the percentage of negative deviations in gray matter in the schizophrenia group (eTable 5), indicating more negatively deviating voxels in patients reporting drug abuse in patients with schizophrenia. This is in line with our expectations as patients that abuse drugs may show a more severe phenotype. However,
we are cautious about the interpretation of this finding because the drug abuse measure we employed is relatively crude and it is impossible given our design to infer any cause/effect relationship (see also the considerations above).
Mean and median images across subjects
Finally, to better understand the effect of potential outliers on our group level deviation statistic images (i.e. to understand whether group level deviations in a given voxel are driven by a small number of outlying subjects) we show a graphical representation of the normalized median deviations across subjects in eFigure 6. In all cases the mean is very similar to the median, suggesting that the role of outliers was minor in each voxel. . pcorr = We use the Bonferroni-Holm method to correct for multiple comparisons. We correct for four comparisons within each patient group. We take the smallest p-value and multiply it by the number of comparisons. If this number remains significant p<0.05 after correction we take the second smallest p-value and multiply by the number of comparisons subtracted by one. We continue this process until the first p-value is not significant, subsequent non-significant p-values are given the number one.; Note: SCZ = All pure Schizophrenia patients and not including those with Schizoaffective and Schizophreniform disorder; BPD = Bipolar disorder I and II; Total medication load is defined in units of directed daily dosage (to standardize across different medications). This was computed by dividing the raw dosage of each medication by the directed daily dosage for that medication and summing across all medications each subject was taking; pcorr = We use the Bonferroni-Holm method to correct for multiple comparisons. We correct for four comparisons within each patient group. We take the smallest p-value and multiply it by the number of comparisons. If this number remains significant p<0.05 after correction, we take the second smallest p-value and multiply by the number of comparisons subtracted by one. We continue this process until the first pvalue is not significant, subsequent non-significant p-values are given the number one. Note: SCZ = All pure Schizophrenia patients, not including those with Schizoaffective and Schizophreniform disorder; BPD = Bipolar disorder; Substance abuse= We combined a measure of lifetime drug abuse from the SCID, combined with a measure from a custom survey (assessing ongoing drug abuse). pcorr = We use the Bonferroni-Holm method to correct for multiple comparisons. We correct for four comparisons within each patient group. We take the smallest p-value and multiply it by the number of comparisons. If this number remains significant p<0.05 after correction, we take the second smallest p-value and multiply by the number of comparisons subtracted by one. We continue this process until the first p-value is not significant, subsequent nonsignificant p-values are given the number one.; eFigures eFigure 1: Characterization of extreme deviations from the normative model in the schizophrenia spectrum. Similar to Figure 4 , we report the group-level mean deviations. Further, the overlap of the most extreme deviations is depicted, representing the percentage of individuals showing an extreme value (|Z| > 2.6) at a specific brain locus. The sub-plot is organized as follows: each one starts with a map of group-level mean deviations (|z| > 2.6), the second plot shows the overlap maps for extreme negative deviations in percentage, the third shows the same for the extreme positive deviations. This figure shows the results for all patients having a diagnosis in the schizophrenia spectrum, thus including patients with schizophrenia, schizoaffective disorder, and schizophreniform disorder. The take home message from this plot is that the results between patients with pure schizophrenia (Figure 4) , and patients belonging to the schizophrenia spectrum do not differ. showing an extreme value (false discovery rate (FDR)-corrected at the 5% level) at a specific brain locus. Each subplot is organized as follows: it starts with a map of group-level mean deviations, the second plot shows the overlap maps for extreme negative deviations in percentage, the third plot shows the same for the extreme positive deviations. From this figure, we can deduce that the conclusions based on Figure 3 ,4,5 remain, when we use the false discovery rate as an initial thresholding criterion.
eFigure 7: Overview of the normative model. In A, the procedure of estimating the normative model in healthy individuals is depicted, with age and gender included as covariates and performing 10-fold crossvalidation. In B, the characterization of the normative model is shown. We see that the normative model changes with age and that from age 20 to 70 years, cortical thickness and surface area is predominantly decreasing. This is true for both females and males and most strongly present in frontal brain regions. In C, we depict the application of the normative model to the different patient groups, including patients with schizophrenia and patients with bipolar disorder. In D, we present the steps that are used to characterize the deviations from the normative model.
